<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114308</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-806</org_study_id>
    <secondary_id>1RC2DA028910-01</secondary_id>
    <nct_id>NCT01114308</nct_id>
  </id_info>
  <brief_title>A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction</brief_title>
  <official_title>A Randomized, Placebo and Active-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Braeburn Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probuphine (buprenorphine implant) is an implant placed just below the skin containing
      buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will
      confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses
      treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CDF of the percent of urine samples negative for opioids in Probuphine and Placebo groups from weeks 1-24</measure>
    <time_frame>1-24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CDF of the percent of urine samples negative for opioids from weeks 1-24 with imputation based on illicit drug use self-report data for Probuphine and placebo groups</measure>
    <time_frame>1-24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDF of the percent of urine samples negative for opioids from weeks 1-16</measure>
    <time_frame>1-16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDF of the percent of urine samples negative for opioids from weeks 17-24</measure>
    <time_frame>17-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of proportion of urine samples negative for illicit opioids over 24 weeks of treatment for Probuphine vs. SL BPN</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent urines negative for illicit opioids</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of study completers</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean total score on the SOWS</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean total score on the COWS</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean subjective opioid craving assessment using Visual Analog Scale (VAS)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient-rated Clinical Global Improvement (CGI)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physician-rated Clinical Global Improvement (CGI)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean total number of weeks of abstinence</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean maximum period of continuous abstinence</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Opioid Dependency</condition>
  <arm_group>
    <arm_group_label>Probuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are first inducted on SL BPN then switched to 4 buprenorphine implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo implant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients are first inducted on SL BPN then switched to 4 placebo implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sublingual buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients are inducted on SL BPN, then continue on SL BPN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probuphine (buprenorphine implant)</intervention_name>
    <description>Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.</description>
    <arm_group_label>Probuphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo implant</intervention_name>
    <description>Implant contains ethylene vinyl acetate</description>
    <arm_group_label>placebo implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>sublingual buprenorphine/naloxone tablets</description>
    <arm_group_label>sublingual buprenorphine</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily provide written informed consent prior to the conduct of any study-related
             procedures

          -  Male or female, 18-65 years of age

          -  Meet DSM-IV-TR criteria for current opioid dependence

          -  Females of childbearing potential or a fertile male, must use a reliable means of
             contraception

        Exclusion Criteria:

          -  Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)

          -  Received any medication-assisted treatment for opioid dependence (e.g., methadone,
             BPN) within the previous 90 days

          -  Current diagnosis of chronic pain requiring opioids for treatment

          -  Candidates for short-term opioid treatment (&lt;6 months) only, or opioid detoxification
             therapy

          -  Pregnant or lactating female?

          -  Previous hypersensitivity or allergy to BPN, EVA-containing substances, or naloxone

          -  Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole
             antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), or
             protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)

          -  History of coagulopathy within the past 90 days, and/or current anti-coagulant therapy
             such as warfarin

          -  Meet the DSM-IV-TR criteria for dependence on any other psychoactive substances other
             than opioids or nicotine (e.g., alcohol, sedatives)

          -  Significant medical or psychiatric symptoms, cognitive impairment, or other factors
             which in the opinion of the Investigator would preclude compliance with the protocol,
             subject safety, adequate cooperation in the study, or obtaining informed consent

          -  Current medical conditions such as severe respiratory insufficiency that may prevent
             the subject from safely participating in study, or any pending legal action that could
             prohibit participation or compliance in the study

          -  Exposure to any investigational drug within the previous 8 weeks

          -  Previous exposure to Probuphine, or prior implantation with a placebo implant in the
             context of a Probuphine clinical trial

          -  Presence of aspartate aminotransferase (AST) levels greater than or equal to 3 X the
             upper limit of normal, alanine aminotransferase (ALT) levels greater than or equal to
             3 X the upper limit of normal, total bilirubin greater than or equal to 1.5 X the
             upper limit of normal, or creatinine greater than 1.5 X upper limit of normal on the
             screening laboratory assessments

          -  Clinically significant low platelet count on the screening laboratory assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine L. Beebe, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Titan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amit Vijapura, MD</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Operation PAR, Inc. - TC Campus</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fidelity Clinical Research, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BPRU, Behavioral Biology Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSTAR: Stanley Street Treatment and Resources, Inc.</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720-6009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York VA Medical Center, NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University, Duke Addictions Program</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Behavioral Health Services</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.titanpharm.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <disposition_first_submitted>October 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 30, 2012</disposition_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>opioid addiction</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>implant</keyword>
  <keyword>methadone</keyword>
  <keyword>heroin</keyword>
  <keyword>suboxone</keyword>
  <keyword>opioid pain medication</keyword>
  <keyword>opioid withdrawal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

